WeVote
Log In

Bill

JA

Bill

HB 6020

Health: research; participation in ibogaine clinical trials; provide for. Amends sec. 7212 of 1978 PA 368 (MCL 333.7212) & adds secs. 2222, 2222a & 2222b.

2025-2026 Regular Session Introduced by Joey Andrews and 21 co-sponsors

Michigan creates a regulated pathway and funding to support FDA-approved ibogaine clinical trials for opioid use disorder and related conditions.

recommendation concurred in
#health:pharmaceuticals #health:research
0
WeVote Research Nonpartisan
Bill Summary · HB 6020

Summary of HB 6020 (2025-2026) – Michigan

Purpose and intent

  • Establishes a framework to support ibogaine-based research and clinical development for treating opioid use disorder (OUD) and related conditions.
  • Creates a dedicated funding mechanism and regulatory structure to facilitate FDA-approved ibogaine clinical trials conducted within Michigan.

Key provisions

  • Ibogaine Grant Program (Sec. 2222(1))

    • Creates the ibogaine grant program within the Department of Health and Human Services (DHHS) to provide grants for certified clinical drug development trials overseen by the FDA.
    • Target conditions include opioid use disorder, co-occurring substance use disorders, and other neurological or mental health conditions for which ibogaine shows efficacy (per FDA-approved protocols).

  • Eligibility for Grants (Sec. 2222(2))

    • Eligible grant recipients must:
    • Be located in Michigan.
    • Demonstrate a history of research and treatment in neurological diseases and substance dependence/trauma.
    • Have a neurosurgery program with appropriate facilities, staff expertise, and capacity to deliver cardiac intensive care services.
    • Show the ability to facilitate pioneering research and innovation in neurological conditions.
    • Either:
      • Have a signed agreement with a multi-state consortium with an FDA IND and a request for FDA Breakthrough Therapy designation, or
      • Be a member of a consortium under Sec. 2222b pursuing an FDA IND and Breakthrough Therapy designation.

  • Ibogaine Research Fund (Sec. 2222(3)-(5))

    • Establishes the ibogaine research fund in the state treasury.
    • Requires deposits from drug development trials or other sources, with the state treasurer managing investments and directing earnings to the fund.
    • DHHS administers the fund for audits and must expend funds, by appropriation, solely for the ibogaine grant program.
    • Promulgates rules to ensure ibogaine administration aligns with an approved IND or, under certain conditions, as directed by the manufacturer of an approved drug (per Sec. 2222a).

  • Funding Allocation (Sec. 2222(8))

    • For the fiscal year ending Sept. 30, 2026, $50,000,000 is appropriated from the Michigan Opioid Healing and Recovery Fund to the ibogaine research fund.
    • Funds must be used consistently with the opioid settlement/claims language from which the money originated.

  • Definitions (Sec. 2222(9))

    • Clarifies terms: certified clinical drug development trial, consortium, fund, ibogaine and ibogaine-based therapeutics, physician, Michigan opioid healing and recovery fund, etc.

  • Prescribing and Administration (Sec. 2222a)

    • If FDA approves ibogaine for a medical condition, only a physician may prescribe ibogaine to a patient.
    • The prescribing physician must supervise administration in a hospital or licensed health facility to ensure safety during ibogaine influence.
    • Administration must comply with rules under Sec. 2222 (and related sections). Federal-law prescribing remains possible.

  • Consortium Framework (Sec. 2222b)

    • Allows DHHS to facilitate a multi-state consortium including:
    • Michigan
    • At least one drug developer or CDMO
    • At least one Michigan higher education institution
    • At least one Michigan hospital/health facility capable of cardiac ICU
    • At least one other state
    • Other states can join if their laws allow it.
    • Before receiving Michigan funds, a consortium must submit an FDA IND under 21 CFR Part 312 and pursue FDA Breakthrough Therapy designation under 21 USC 356.

  • Controlled Substances Scheduling (Sec. 7212)

    • Confirms ibogaine’s status: ibogaine used for research under the grant program (Sec. 2222) or prescribed under Sec. 2222a is not considered a Schedule I controlled substance for purposes of this act.
    • Also clarifies marijuana/cannabis scheduling context (Schedule II if compliant with state law and federal authority) and reaffirms federal IND/Breakthrough processes.

Affected parties and scope

  • Primary: Michigan Department of Health and Human Services; Michigan institutions (hospitals, neurosurgery programs, universities); drug developers/CDMOs; researchers conducting FDA-approved ibogaine trials.
  • Indirectly: Patients with OUD or other qualifying conditions who may participate in ibogaine clinical trials; operators of facilities that would administer ibogaine under strict supervision and regulatory rules.

Procedural and timeline aspects

  • Initial funding allocation of $50 million from the Michigan Opioid Healing and Recovery Fund is designated for the 2026 fiscal year (ending Sept 30, 2026).
  • The bill outlines required steps for consortia, including formation, IND submission to FDA, and pursuit of Breakthrough Therapy designation before receiving state funds.
  • The act would require DHHS to promulgate rules governing administration and facility requirements, aligned with approved INDs or manufacturer directions where applicable.

Notes

  • The bill does not by itself legalize ibogaine for general use; it creates a regulated pathway to support and fund FDA-regulated clinical trials in Michigan.
  • It ties financial appropriations to compliance with existing opioid settlement provisions and maintains strict professional and clinical supervision requirements for ibogaine administration.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.